What was keytruda's initial cancer indication?

What cancer did Keytruda (pembrolizumab) start with?

Keytruda’s initial FDA-approved cancer indication was for treatment of unresectable or metastatic melanoma.

What was the exact wording of the first approval?

The first approval covered patients with unresectable or metastatic melanoma that had progressed following ipilimumab (or after anti–CTLA-4 therapy) and, when the patient had a BRAF V600 mutation, after BRAF-targeted therapy.

When was that first indication approved?

Keytruda (pembrolizumab) received its initial FDA approval in 2014 for the melanoma indication described above.